
Puma Biotechnology Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $3.3433
- Today's High:
- $3.46
- Open Price:
- $3.42
- 52W Low:
- $2.08
- 52W High:
- $5.16
- Prev. Close:
- $3.39
- Volume:
- 92604
Company Statistics
- Market Cap.:
- $161.06 million
- Book Value:
- 0.648
- Revenue TTM:
- $230.12 million
- Operating Margin TTM:
- 12.46%
- Gross Profit TTM:
- $172.94 million
- Profit Margin:
- -1.06%
- Return on Assets TTM:
- 9.09%
- Return on Equity TTM:
- -9.73%
Company Profile
Puma Biotechnology Inc had its IPO on 2012-04-24 under the ticker symbol PBYI.
The company operates in the Healthcare sector and Biotechnology industry. Puma Biotechnology Inc has a staff strength of 192 employees.
Stock update
Shares of Puma Biotechnology Inc opened at $3.42 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.34 - $3.46, and closed at $3.36.
This is a -0.89% slip from the previous day's closing price.
A total volume of 92,604 shares were traded at the close of the day’s session.
In the last one week, shares of Puma Biotechnology Inc have slipped by -9.19%.
Puma Biotechnology Inc's Key Ratios
Puma Biotechnology Inc has a market cap of $161.06 million, indicating a price to book ratio of 9.0642 and a price to sales ratio of 1.0452.
In the last 12-months Puma Biotechnology Inc’s revenue was $230.12 million with a gross profit of $172.94 million and an EBITDA of $38.42 million. The EBITDA ratio measures Puma Biotechnology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Puma Biotechnology Inc’s operating margin was 12.46% while its return on assets stood at 9.09% with a return of equity of -9.73%.
In Q2, Puma Biotechnology Inc’s quarterly earnings growth was a negative -78.1% while revenue growth was a negative 8.3%.
Puma Biotechnology Inc’s PE and PEG Ratio
- Forward PE
- 11.2867
- Trailing PE
- 0
- PEG
- 0.03
Its diluted EPS in the last 12-months stands at $-0.07 per share while it has a forward price to earnings multiple of 11.2867 and a PEG multiple of 0.03. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Puma Biotechnology Inc’s profitability.
Puma Biotechnology Inc stock is trading at a EV to sales ratio of 1.0921 and a EV to EBITDA ratio of 7.8677. Its price to sales ratio in the trailing 12-months stood at 1.0452.
Puma Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $200.49 million
- Total Liabilities
- $60.29 million
- Operating Cash Flow
- $-4683000.00
- Capital Expenditure
- $68000
- Dividend Payout Ratio
- 0%
Puma Biotechnology Inc ended 2025 with $200.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $200.49 million while shareholder equity stood at $30.40 million.
Puma Biotechnology Inc ended 2025 with $0 in deferred long-term liabilities, $60.29 million in other current liabilities, 5000.00 in common stock, $-1363228000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $60.01 million and cash and short-term investments were $74.44 million. The company’s total short-term debt was $15,792,000 while long-term debt stood at $87.62 million.
Puma Biotechnology Inc’s total current assets stands at $118.55 million while long-term investments were $0 and short-term investments were $14.43 million. Its net receivables were $31.29 million compared to accounts payable of $7.80 million and inventory worth $7.63 million.
In 2025, Puma Biotechnology Inc's operating cash flow was $-4683000.00 while its capital expenditure stood at $68000.
Comparatively, Puma Biotechnology Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $3.36
- 52-Week High
- $5.16
- 52-Week Low
- $2.08
- Analyst Target Price
- $4.75
Puma Biotechnology Inc stock is currently trading at $3.36 per share. It touched a 52-week high of $5.16 and a 52-week low of $5.16. Analysts tracking the stock have a 12-month average target price of $4.75.
Its 50-day moving average was $3.53 and 200-day moving average was $3.61 The short ratio stood at 10.2 indicating a short percent outstanding of 0%.
Around 1516.4% of the company’s stock are held by insiders while 5995.5% are held by institutions.
Frequently Asked Questions About Puma Biotechnology Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company’s drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.